1.83

0.00% 0.00

After Hours: 1.82 -0.01 -0.55%

C 4 Therapeutics Inc (CCCC)

Overview News Price History Option Chain Financials Discussions Forecast

C 4 Therapeutics Inc stock is traded at $1.83, with a volume of 622.54K. It is up +0.00% in the last 24 hours and down -14.08% over the past month. C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients' lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. Its degrader medicines are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT1946, and CFT8919.

Previous Close:

$1.83

Open:

$1.8

24h Volume:

622.54K

Relative Volume:

0.41

Market Cap:

$177.35M

Revenue:

$20.76M

Net Income/Loss:

$-132.49M

P/E Ratio:

-0.6854

EPS:

-2.67

Net Cash Flow:

$-108.55M

1W Performance:

+7.02%

1M Performance:

-14.08%

6M Performance:

-18.30%

1Y Performance:

-44.55%

1-Day Range:

$1.78

$1.87

1-Week Range:

$1.725

$1.90

52-Week Range:

$1.085

$3.65

C 4 Therapeutics Inc Stock (CCCC) Company Profile

Name

C 4 Therapeutics Inc

Sector

Healthcare (1112)

Industry

Biotechnology (621)

Phone

(617) 231-0700

Address

490 ARSENAL WAY, WATERTOWN

Employee

110

Twitter

Next Earnings Date

2025-02-24

Latest SEC Filings

CCCC's Discussions on Twitter

Compare CCCC vs VRTX, REGN, ARGX, ALNY, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
CCCC C 4 Therapeutics Inc	1.83	177.35M	20.76M	-132.49M	-108.55M	-2.67
VRTX Vertex Pharmaceuticals Inc	465.02	117.03B	11.74B	3.68B	3.34B	14.19
REGN Regeneron Pharmaceuticals Inc	783.65	82.35B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	833.54	51.64B	3.06B	1.28B	447.35M	19.67
ALNY Alnylam Pharmaceuticals Inc	308.48	42.58B	3.21B	43.57M	221.36M	0.2405
ONC Beone Medicines Ltd Adr	346.42	38.87B	4.98B	69.60M	525.67M	0.5198

C 4 Therapeutics Inc Stock (CCCC) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-02-25	Initiated	TD Cowen	Buy
Sep-17-25	Initiated	Barclays	Overweight
Sep-15-25	Upgrade	Stephens	Equal-Weight → Overweight
Sep-04-25	Initiated	Guggenheim	Buy
Dec-19-24	Upgrade	Wells Fargo	Equal Weight → Overweight
Nov-18-24	Initiated	Stephens	Equal-Weight
Jan-29-24	Upgrade	JP Morgan	Underweight → Neutral
Dec-13-23	Upgrade	Stifel	Hold → Buy
Feb-24-23	Upgrade	Credit Suisse	Underperform → Neutral
Feb-24-23	Downgrade	JP Morgan	Neutral → Underweight
Nov-04-22	Downgrade	JP Morgan	Overweight → Neutral
Oct-11-22	Initiated	Morgan Stanley	Underweight
Apr-28-22	Initiated	Credit Suisse	Underperform
Apr-11-22	Downgrade	BofA Securities	Buy → Neutral
Mar-10-22	Initiated	JP Morgan	Overweight
Feb-11-22	Resumed	BMO Capital Markets	Outperform
Feb-10-22	Initiated	Wells Fargo	Equal Weight
Nov-23-21	Initiated	BofA Securities	Buy
Oct-14-21	Initiated	SVB Leerink	Mkt Perform
Sep-30-21	Initiated	Stifel	Hold
Jun-04-21	Initiated	H.C. Wainwright	Buy
Mar-31-21	Initiated	BMO Capital Markets	Outperform
Oct-28-20	Initiated	UBS	Buy
Oct-27-20	Initiated	BMO Capital Markets	Outperform
Oct-27-20	Initiated	Jefferies	Buy

View All

C 4 Therapeutics Inc Stock (CCCC) Latest News

Feb 11, 2026

C4 Therapeutics Maps Cemsidomide Phase II Launch, BCMA Combo Plans at Guggenheim Conference - MarketBeat

Feb 11, 2026

Biotech Mineralys offers 4-year stock awards to new hires - Stock Titan

Feb 11, 2026

Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

Feb 11, 2026

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire

Feb 11, 2026

Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - The Globe and Mail

Feb 11, 2026

BridgeBio Oncology Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

Feb 11, 2026

Feb 10, 2026

LB Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

Feb 10, 2026

What Does The Institutional Ownership Tell Us About C4 Therapeutics? - simplywall.st

Feb 10, 2026

Feb 09, 2026

C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

Feb 09, 2026

New C4 Therapeutics hire receives options on 162,880 shares - Stock Titan

Feb 09, 2026

Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

Feb 09, 2026

Feb 06, 2026

Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - markets.businessinsider.com

Feb 06, 2026

Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

Feb 06, 2026

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

Feb 06, 2026

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

Feb 06, 2026

Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Intellia Therapeutics

Feb 06, 2026

Feb 05, 2026

Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

Feb 05, 2026

Bicara Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

Feb 05, 2026

Feb 04, 2026

Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - GlobeNewswire

Feb 04, 2026

C4 Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026 - The Manila Times

Feb 04, 2026

C4 Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026 - GlobeNewswire Inc.

Feb 04, 2026

Feb 03, 2026

Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

Feb 03, 2026

Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

Feb 03, 2026

Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance

Feb 03, 2026

KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire

Feb 03, 2026

Feb 02, 2026